Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT)

Despite the toxicity of imatinib, QoL was not impaired in this fragile patient population. The benefits of imatinib rechallenge outweigh its toxicities, supporting its clinical relevance for patients without active treatment options.